BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the expansion of its Deep TMS™ platform along the East Coast of the U.S. through the recent order of 14 new systems by a large and growing enterprise network.

BrainsWay Ltd.（纳斯达克和塔斯社：BWAY）（“BrainsWay”或“该公司”）是治疗精神健康障碍的先进无创神经刺激疗法的全球领导者，今天宣布通过一个大型且不断发展的企业网络最近订购的14个新系统，在美国东海岸扩展其深度TMS™平台。

The large order follows other recent multisystem orders placed with the Company, further strengthening its position as the preferred choice for many mental health providers..

这一大订单紧随着该公司最近收到的其他多系统订单，进一步巩固了其作为许多心理健康服务提供者首选的地位。。

“We are pleased to continue to expand the presence of Deep TMS therapy on the East Coast of the U.S. and support the growth of this large enterprise network through their order for 14 of our innovative Deep TMS devices” said Hadar Levy, BrainsWay’s Chief Executive Officer. “This latest order aligns with our strategic goal of cultivating strong relationships with a variety of mental health groups and networks, which we believe affords us the best opportunity for long-term profitable growth.”.

BrainsWay首席执行官哈达尔·利维（HadarLevy）表示：“我们很高兴继续扩大深度TMS治疗在美国东海岸的业务，并通过订购我们14款创新的深度TMS设备来支持这一大型企业网络的发展。”。“这一最新订单符合我们与各种心理健康团体和网络建立牢固关系的战略目标，我们认为这为我们提供了长期盈利增长的最佳机会。”。

As of June 30, 2024, BrainsWay had an installed base of 1,215 Deep TMS systems.

截至2024年6月30日，BrainsWay拥有1215个深度TMS系统的安装基础。

About BrainsWay

关于BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy.

BrainsWay是治疗精神健康障碍的先进无创神经刺激疗法的全球领导者。该公司凭借其专有的深度经颅磁刺激（Deep TMS™）平台技术，大胆推进神经科学，以改善健康和改变生活。BrainsWay是第一家也是唯一一家获得FDA批准的三种适应症的TMS公司，这些适应症得到了关键临床研究的支持，证明了临床证明的疗效。

Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence.

目前的适应症包括重度抑郁症（包括减轻焦虑症状，通常称为焦虑抑郁），强迫症和吸烟成瘾。该公司致力于通过卓越的科学领先，并以其无与伦比的临床证据为基础。

Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com..

深度TMS在各种精神，神经和成瘾性疾病中的其他临床试验正在进行中。BrainsWay成立于2003年，在马萨诸塞州伯灵顿和以色列耶路撒冷设有办事处，致力于提高全球对深度TMS的认识和广泛访问。有关BrainsWay的最新消息和信息，请访问www.BrainsWay.com。。

Forward-Looking Statement

前瞻性声明

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的“前瞻性声明”。这些陈述之前可能会有“打算”、“可能”、“将会”、“计划”、“期望”、“预期”、“项目”、“预测”、“估计”、“目标”、“相信”、“希望”、“潜在”或类似的词语。

These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise.

这些前瞻性声明及其影响仅基于公司管理层当前的期望，并受到许多因素和不确定性的影响，这些因素和不确定性可能导致实际结果与前瞻性声明中描述的结果存在重大差异。此外，科学研究和临床研究的历史结果或结论不能保证未来的结果会提出类似的结论，或者本文提到的历史结果会根据其他研究或其他方式进行类似的解释。

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Com.

除其他因素外，以下因素可能导致实际结果与前瞻性报表中描述的结果存在重大差异：财务资源不足，无法满足未来的资本要求；技术和市场需求的变化；启动和/或成功完成计划研究和临床试验的延迟或障碍；未能在公司预期的时间范围内或根本没有获得监管机构的批准；无法留住或吸引对Deep TMS产品开发至关重要的关键员工；深度TMS产品和流程出现不可预见的困难，和/或无法开发必要的增强功能；与Deep TMS产品相关的意外成本；未能获得并维持对公司知识产权的充分保护，包括许可给Com的知识产权。

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

本新闻稿中的任何前瞻性声明仅在本新闻稿发布之日起生效。公司没有义务公开更新或审查任何前瞻性声明，无论是由于新信息、未来发展还是其他原因，除非任何适用的证券法可能要求。

More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission..

有关影响公司的风险和不确定性的更多详细信息，请参见公司向美国证券交易委员会提交的文件中的“风险因素”标题。。

Contacts:

联系人：

BrainsWay:

BrainsWay公司：

Ido Marom

伊多·马龙

Chief Financial Officer

首席财务官

[email protected]

[受电子邮件保护]

Investors:

投资者：

Brian Ritchie

布莱恩·里奇

LifeSci Advisors LLC

LifeSci顾问有限公司

[email protected]

[受电子邮件保护]

Source: globenewswire.com

来源：globenewswire.com